Audentes Therapeutics (BOLD) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Audentes Therapeutics (NASDAQ:BOLD) from a sell rating to a hold rating in a report published on Wednesday morning.

BOLD has been the subject of several other research reports. Zacks Investment Research upgraded shares of Audentes Therapeutics from a hold rating to a buy rating and set a $37.00 target price for the company in a report on Thursday, March 8th. HC Wainwright set a $37.00 target price on shares of Audentes Therapeutics and gave the stock a buy rating in a report on Friday, March 9th. BidaskClub cut shares of Audentes Therapeutics from a strong-buy rating to a buy rating in a report on Wednesday, December 6th. Wedbush restated an outperform rating and set a $56.00 target price on shares of Audentes Therapeutics in a report on Friday, March 9th. Finally, Cowen restated a buy rating on shares of Audentes Therapeutics in a report on Friday, March 9th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $35.56.

How to Become a New Pot Stock Millionaire

Audentes Therapeutics stock opened at $28.11 on Wednesday. Audentes Therapeutics has a twelve month low of $13.90 and a twelve month high of $41.80.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.09. equities research analysts expect that Audentes Therapeutics will post -3.43 EPS for the current fiscal year.

In other Audentes Therapeutics news, VP Suyash Prasad sold 1,900 shares of the company’s stock in a transaction on Monday, March 26th. The shares were sold at an average price of $30.00, for a total transaction of $57,000.00. Following the sale, the vice president now directly owns 1,900 shares of the company’s stock, valued at $57,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Louis G. Lange sold 48,000 shares of the company’s stock in a transaction on Monday, March 26th. The stock was sold at an average price of $28.89, for a total transaction of $1,386,720.00. Following the sale, the director now directly owns 414,231 shares in the company, valued at $11,967,133.59. The disclosure for this sale can be found here. Insiders have sold 1,138,107 shares of company stock valued at $39,502,022 in the last 90 days. 47.30% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in Audentes Therapeutics during the third quarter worth $143,000. Teacher Retirement System of Texas bought a new stake in Audentes Therapeutics during the fourth quarter worth $208,000. MetLife Investment Advisors LLC bought a new stake in Audentes Therapeutics during the fourth quarter worth $248,000. Trexquant Investment LP bought a new stake in Audentes Therapeutics during the third quarter worth $295,000. Finally, Virtus Fund Advisers LLC bought a new stake in Audentes Therapeutics during the fourth quarter worth $372,000. 66.96% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Audentes Therapeutics (BOLD) Stock Rating Upgraded by ValuEngine” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3340521/audentes-therapeutics-bold-stock-rating-upgraded-by-valuengine.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Raymond James Reaffirms Buy Rating for TG Therapeutics
Raymond James Reaffirms Buy Rating for TG Therapeutics
ValuEngine Lowers Taiwan Semiconductor Mfg.  to Buy
ValuEngine Lowers Taiwan Semiconductor Mfg. to Buy
Zacks Investment Research Lowers The J.M. Smucker  to Hold
Zacks Investment Research Lowers The J.M. Smucker to Hold
Team  Raised to “Sell” at ValuEngine
Team Raised to “Sell” at ValuEngine
Transocean  Price Target Raised to $13.00
Transocean Price Target Raised to $13.00
Sanchez Energy  Downgraded to “Hold” at KLR Group
Sanchez Energy Downgraded to “Hold” at KLR Group


Leave a Reply

© 2006-2018 Ticker Report. Google+.